Hautmann S, Huland E, Wullbrand A, Friedrich M, Huland H
Department of Urology, University Hospital Hamburg-Eppendorf, Martintistr. 52, 20246 Hamburg, Germany.
Anticancer Res. 2000 Nov-Dec;20(6B):4495-8.
We studied the influence of interleukin-2 (IL-2) therapy on tumor growth and prevention of metastasis in metastatic, hormone-refractory prostatic carcinoma (PCa) in an animal model orthotopically (ortho) and subcutaneously (s.c.).
75 juvenile male Copenhagen rats were divided into five groups of 15 rats each. MatLyLu-PCa (MLL) was implanted ortho (n = 30) in 2 groups or s.c. (n = 30) in 2 groups and were treated locally at the tumor site with micro-osmotic pumps. The rats in 2 groups received IL-2 pumps with 36 x 10(6) IU of IL-2 and the rats in 2 other groups were treated with pumps delivering albumin only as a control. The rats in the last group received ortho MLL and s.c. IL-2 (n = 15). Survival time was then monitored.
Prostatic tumor was found in all ortho animals. Additionally lymphogenic and pulmonary metastasis was found in all animals. The orthotopic and s.c. IL-2-treated groups showed a statistically significantly increased survival compared with the orthotopic and s.c. albumin-treated groups. When treating the ortho MLL with s.c. IL-2 there was still a statistically significant longer survival than in the control groups.
IL-2 therapy significantly reduces tumor growth of rats with metastatic, hormone-refractory prostatic cancer MatLyLu.
我们在原位（ortho）和皮下（s.c.）动物模型中研究了白细胞介素-2（IL-2）治疗对转移性、激素难治性前列腺癌（PCa）肿瘤生长和转移预防的影响。
75只幼年雄性哥本哈根大鼠分为5组，每组15只。MatLyLu-PCa（MLL）在2组大鼠中原位植入（n = 30），在另外2组大鼠中皮下植入（n = 30），并在肿瘤部位用微渗透泵进行局部治疗。2组大鼠接受含36×10⁶IU IL-2的泵治疗，另外2组大鼠用仅输送白蛋白的泵作为对照。最后一组大鼠接受原位MLL和皮下IL-2治疗（n = 15）。然后监测生存时间。
所有原位植入动物均发现前列腺肿瘤。此外，所有动物均发现淋巴转移和肺转移。与原位和皮下白蛋白治疗组相比，原位和皮下IL-2治疗组的生存时间在统计学上显著延长。当用皮下IL-2治疗原位MLL时，其生存时间在统计学上仍显著长于对照组。
IL-2治疗可显著降低转移性、激素难治性前列腺癌MatLyLu大鼠的肿瘤生长。
